The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.
about
Mechanisms of action of glucagon-like peptide 1 in the pancreasDirected differentiation of rhesus monkey ES cells into pancreatic cell phenotypesAn Update on the Effect of Incretin-Based Therapies on β-Cell Function and MassEpigenetics: the missing link to understanding β-cell dysfunction in the pathogenesis of type 2 diabetesInterventions to preserve beta-cell function in the management and prevention of type 2 diabetesβ-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesGLP-1 improves neuropathology after murine cold lesion brain traumaIn vitro proliferation of adult human beta-cellsDevelopment, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris.Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor AgonistsLaboratory animals as surrogate models of human obesity.Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial.The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes.Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.Genistein induces pancreatic beta-cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in miceGlucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.Baicalein Protects against Type 2 Diabetes via Promoting Islet β-Cell Function in Obese Diabetic Mice.Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.Re-expression of IGF-II is important for beta cell regeneration in adult miceEfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trActivation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell massEffects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic conditionThe effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controlsExendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets.Development of a nongenetic mouse model of type 2 diabetes.Small Molecule Kaempferol Promotes Insulin Sensitivity and Preserved Pancreatic β -Cell Mass in Middle-Aged Obese Diabetic MiceExtending residence time and stability of peptides by protected graft copolymer (PGC) excipient: GLP-1 example.Importance of Beta Cell Function for the Treatment of Type 2 DiabetesGut peptides in the treatment of diabetes mellitus.Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.Incretin mimetics as emerging treatments for type 2 diabetes.Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db MiceStructure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes.Development and application of rodent models for type 2 diabetes.
P2860
Q24683764-020105A4-1BC8-4C29-BE52-83E401199882Q24802550-11055CA5-72C0-4D52-8115-C96548FDE456Q26749089-29282E79-7E63-4B36-8AA2-9202415EC067Q26823288-089DFE6D-ADDC-4E4A-AAF5-74001A14C0A0Q26830871-14956D9E-0E60-4302-B271-73AA3AAC539AQ27692665-1639D86E-1C15-4248-8EF9-C1DCF5FE4957Q28067465-91238D74-D4C4-4032-89CE-0460D9AE2926Q28651569-2D16113F-F6B2-4F3B-A0C1-4DD210DE3F37Q28730317-FFB1AFF7-BF96-448F-BC96-4B742DB53DCFQ33415965-2826AD66-07F6-4890-B0CC-73E464917B27Q33521451-004557E7-55EB-41F9-B39C-D79D81110FE7Q33567304-49034C39-EF84-4F1F-9BD3-AA8ED66F8490Q33585850-6F81BA7B-A53D-407B-9B68-38A5FE0419CCQ33603369-DD212CED-EE46-469B-B4D5-A3A5EB7D2BB0Q33603384-58CBFBAC-8F9E-44E2-A7A2-71E57D72F186Q33608023-699649C1-0E98-4F25-81E9-639490786666Q33785308-FEFF1B2E-AB2F-4F86-816A-DC3EB71D6C86Q33826388-29360935-7077-4DAC-8791-1DA1D69DED8DQ33993882-2D743C0C-A460-45D0-88FE-C3662B754861Q34026346-631863B0-7E92-47CD-A61C-D2115102DCB8Q34043054-47E6487B-D116-4A2B-ABA0-E06776F8E8DFQ34381400-A64AC6AE-D88E-4B71-BBE9-0C28D2540A34Q34412090-29ED1C23-A467-4914-8C9E-A68444CE8E39Q34598940-C57CABDD-AAC7-4E8F-9838-8F0E7C854B09Q34893192-F2322069-5C07-47FA-9754-70E7BAC2E6EAQ35055522-7B9CBBB7-DCF1-42BC-8CD2-AE776C623961Q35184904-3EA19F37-2F0F-4ED5-A46D-7A85121A5ED0Q35312833-DD5A97D3-83F7-49E0-91BA-6ED23CEA7EC2Q35563969-8A929519-0687-4CAC-A546-684F2F2E3D31Q35580004-354209D0-E441-4123-99A5-EF6A2B71F5C9Q35630601-65F3820C-411A-4AB4-9B3C-028BA25AC9B4Q35638672-93839635-4FFF-40EF-AC28-BCA433C8871BQ35667116-8F24F1FC-F58A-4E87-B4BB-95306B02AF36Q35688209-D3966768-5818-42F9-9F91-0DB124D8A977Q35772029-D21B317B-4AC8-49F6-A291-3F48B5FA42ABQ35962037-DEF87D27-FFE9-415C-A31D-97B56F914046Q35962745-195A3668-5D7E-4E4C-9D83-BE3BBC442025Q36006629-D6CD313A-39B4-447F-81EC-B196A6AE5183Q36106470-ED4B6D66-01D9-4E4C-93D7-375019049BE4Q36162483-BB7C0357-8A54-45C4-A961-FBEA2D0A73BC
P2860
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
The long-acting GLP-1 derivati ...... ta-cell mass in diabetic mice.
@en
type
label
The long-acting GLP-1 derivati ...... ta-cell mass in diabetic mice.
@en
prefLabel
The long-acting GLP-1 derivati ...... ta-cell mass in diabetic mice.
@en
P2093
P2860
P1476
The long-acting GLP-1 derivati ...... ta-cell mass in diabetic mice.
@en
P2093
Bidda Rolin
Carsten F Gotfredsen
Marianne O Larsen
Michael Wilken
Richard D Carr
P2860
P304
P356
10.1152/AJPENDO.00030.2002
P577
2002-10-01T00:00:00Z